Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Oct 17, 2019	CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019 BRISBANE, Calif. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Oct 08, 2019	CareDx Participates in Transplant Roundtable with Senator Durbin CareDx joins UI Health and NKF to meet with Senator Durbin and advocate for action on anti-rejection drug coverage for kidney transplant patients BRISBANE, Calif. , Oct. 08, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery,	View HTML
Toggle Summary Sep 26, 2019	CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor CareDx protects transplantation innovation by enforcing patent protection BRISBANE, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Sep 24, 2019	CareDx Adds HistoMap To Testing Portfolio CareDx partners with NanoString to improve precision of transplant biopsies BRISBANE, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Sep 23, 2019	CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication Artificial Intelligence algorithm predicts long-term kidney transplant outcomes BRISBANE, Calif. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated,	View HTML
Toggle Summary Sep 20, 2019	CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting AlloSeq Tx 17 is a best in class HLA typing solution with the most comprehensive sequencing and easiest workflow BRISBANE, Calif. , Sept. 20, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of	View HTML
Toggle Summary Sep 18, 2019	First Patient Enrolled in Landmark CareDx OKRA Registry CareDx drives best in class 4,000 transplant patient registry with KOAR and OKRA BRISBANE, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated,	View HTML
Toggle Summary Sep 17, 2019	CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference BRISBANE, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Sep 12, 2019	CareDx launches AlloSeq® cfDNA at ESOT 2019 CareDx will establish access to dd-cfDNA surveillance solutions for transplant patients worldwide BRISBANE, Calif. , Sept. 12, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Sep 11, 2019	CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML